News Release 

Researchers investigate molecule, VISTA, which keeps immune system quiet against cancer

A research team led by Dartmouth's Norris Cotton Cancer Center learns how a certain immune checkpoint inhibitor molecule acts like 'brakes,' quieting the immune system from responding to cancer

Dartmouth-Hitchcock Medical Center

LEBANON, NH - While strong immune responses are needed to help protect the host from infections, the immune system also must curb the magnitude of those responses to limit the damage it can potentially cause. Over the past 8-10 years, a team of researchers at Dartmouth's and Dartmouth Hitchcock's Norris Cotton Cancer Center, led by Randolph Noelle, PhD, have identified some of the molecules that the immune system uses to temper immunity. While these molecules are usually good, they also limit the magnitude of the immune response to cancer. The team has learned that turning off these "brakes" on immunity allows therapeutic response to cancer. VISTA (V-domain Ig suppressor of T-cell activation) is one of these tempering molecules that negatively regulates immunity.

The team describes how VISTA controls immune T-cell responses in their study, "VISTA, a checkpoint regulator of naïve T-cell quiescence and tolerance in the periphery," newly published in Science.

"We have learned that keeping your immune system quiet is a challenging and very active process," says Noelle. "VISTA mediates immune system function and its loss can result in the development of unwanted immune responses. But VISTA may also be a valuable target in regulating the immune response in cancer and autoimmunity."

VISTA keeps the immune system's T-cell compartment passive and prevents activation of the immune system to self-antigens such as developing cancer cells. "Like other negative checkpoint regulators, blocking VISTA in cancer may enhance the host's ability to make protective tumor-specific immune responses," says Noelle.

Currently, there is an antibody specific to VISTA that is going to be used in Phase I clinical trials in cancer to see if it is safe and if it can amplify the immune response to cancer in patients. If so, this antibody may be valuable in the development of drugs and vaccines to provide therapeutic response to cancer and cancer cures.

###

Randolph Noelle, PhD, is a Kosasa Distinguished Professor of Microbiology and Immunology at Dartmouth's Geisel School of Medicine and member of the Immunology and Cancer Immunotherapy Research Program at Dartmouth's and Dartmouth-Hitchcock's Norris Cotton Cancer Center. His research in immunobiology focuses on T-cell function, antibody-based immunotherapy and cellular vaccines for cancer. Noelle is the co-founder of ImmuNext, a company that develops immunoregulatory drugs.

About Norris Cotton Cancer Center at Dartmouth-Hitchcock

Norris Cotton Cancer Center combines advanced cancer research at Dartmouth's Geisel School of Medicine with patient-centered cancer care provided at Dartmouth-Hitchcock Medical Center in Lebanon, NH, at Dartmouth-Hitchcock regional locations in Manchester, Nashua and Keene, NH, and St. Johnsbury and Bennington, VT, and at partner hospitals throughout New Hampshire and Vermont. It is one of 51 centers nationwide to earn the National Cancer Institute's "Comprehensive Cancer Center" designation. Learn more about Norris Cotton Cancer Center research, programs, and clinical trials online at cancer.dartmouth.edu.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.